期刊文献+

抗结核新药贝达喹啉临床应用专家共识 被引量:74

原文传递
导出
摘要 目前,结核病仍然是危害人类健康的主要传染性疾病。2017年世界卫生组织全球结核病报告显示,2016年全球结核病发病人数为1 040万,其中耐多药结核病(multidrug-resistant tuberculosis,MDR-TB)和利福平耐药结核病(rifampicin-resistant tuberculosis, RR-TB)新发病例60万,广泛耐药结核病(extensively drug-resistant tuberculosis,XDR-TB)新发病例3万。
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2018年第6期461-466,共6页 Chinese Journal of Tuberculosis and Respiratory Diseases
  • 相关文献

参考文献2

二级参考文献43

  • 1唐神结.结核病临床诊治进展年度报告(2011)[M] .北京:人民卫生出版社,2012.6:5.
  • 2唐神结.结核病临床诊治进展年度报告(2012)[M].北京:人民卫生出版社,2013:79-158.
  • 3World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. WHO/HTM/TB/2013.06. Geneva: World Health Organization, 2013.
  • 4World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-re- sistant tuberculosis. WHO/HTM/TB/2014. 11. Geneva~ World Health Organization, 2014.
  • 5Andries K, Verhasselt P, Guillemont J, et al. A diarylquino- line drug active on the ATP synthase of Mycobacterium tubercu- losis. Science, 2005, 307(5707):223-227.
  • 6Koul A, Vranckx L, Dhar N, et al. Delayed bactericidal re- sponse of Mycobacteriurn tuberculosis to bedaquiline involves re- modelling of bacterial metabolism. Nat Commun, 2014, 5 : 3369.
  • 7Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med, 2009, 360(23) :2397-2405.
  • 8Diacon AH,Pym A, Grobusch MP, ef al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med, 2014, 371(8): 723 732.
  • 9Cox E, Laessig K. FDA approval of bedaquiline~the benefit- risk balance for drug-resistant tuberculosis. N Engl J Med, 2014, 371(8): 689 691.
  • 10WHO. Global tuberculosis report 2014 [ M ]. Geneva,Switzerland: WHO, 2014.

共引文献10

同被引文献424

引证文献74

二级引证文献524

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部